LOUISVILLE, Ky.--(BUSINESS WIRE)--USWM, LLC (US WorldMeds) today announced that the U.S. Food and Drug Administration (FDA) has approved IWILFIN™ (eflornithine) 192 mg tablets, a groundbreaking oral ...
The FDA approved oral eflornithine (Iwilfin) for children and adults with high-risk neuroblastoma, the agency announced on Wednesday. Specifically, the ornithine decarboxylase inhibitor is indicated ...
Eflornithine plus Gleostine improved OS and PFS in recurrent grade 3 IDH-mutated astrocytoma compared to Gleostine alone. The STELLAR study reclassified patients using updated WHO 2021 criteria, ...
Eflornithine plus lomustine improved survival in recurrent grade 3 IDH-mutant astrocytoma compared to lomustine alone, with significant gains in progression-free and overall survival. The STELLAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results